| Literature DB >> 28204904 |
Nina Hallowell1, Shirlene Badger2, Sue Richardson3,4, Carlos Caldas3,4, Richard H Hardwick5,2,3,4,6,7, Rebecca C Fitzgerald3,6, Julia Lawton7.
Abstract
Reproductive genetic testing- PreNatal Diagnosis (PND) and Preimplantation Genetic Diagnosis (PGD)-for CDH1 mutations associated with Hereditary Diffuse Gastric Cancer (HDGC)is available in the UK. This qualitative interview study examined high-risk individuals' (n = 35) views of CDH1 reproductive genetic testing. Interviewees generally regarded reproductive genetic testing as an acceptable form of HDGC risk management. However, some were concerned that their genetic risks required them to plan reproduction and anticipated difficulties communicating this to reproductive partners. Individuals had a preference for PGD over PND because it avoided the need for a termination of pregnancy. However, those who had not yet had children expressed concerns about having to undergo IVF procedures and worries about their effectiveness and the need for embryo selection in PGD. It is suggested that high-risk individuals are provided with access to reproductive genetic counselling.Entities:
Keywords: E-Cadherin (CDH1); Hereditary cancer; Hereditary diffuse gastric cancer (HDGC); Preimplantation genetic diagnosis (PGD); Prenatal diagnosis (PND); Reproductive genetic testing
Mesh:
Substances:
Year: 2017 PMID: 28204904 PMCID: PMC6061929 DOI: 10.1007/s10689-017-9976-y
Source DB: PubMed Journal: Fam Cancer ISSN: 1389-9600 Impact factor: 2.375